Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

Indian Medtech Firms Want Level Playing Field On Tariffs And Action On US Non-Tariffs Barriers

 
• By Shubham Singh

India’s medical technology industry is raising the alarm over steep new US tariffs on imported medical devices. It argues for structural change to address “unequal regulatory access” and non-tariff barriers.

Indian medtech industry leaders now argue that the potential benefits may be limited if systemic trade imbalances and regulatory hurdles are not addressed.
Key Takeaways

· AiMeD calls for tariff parity and reciprocal regulatory access as US imposes import duty of 27%, reduced to 10% for 90 days.

· Industry says Indian customs duties, among the lowest globally for medical devices, “must be addressed.”.

· Non-tariff barriers such as high US registration fees and lengthy clinical trials are “real roadblocks to Indian medtech exports” and far outweigh the impact of tariffs.

India’s medtech sector is voicing strong concerns about US President Trump’s 27% reciprocal tariff on imports from India. The tariff...

More from Asia

More from Medtech Insight